Spots Global Cancer Trial Database for expanded access

Every month we try and update this database with for expanded access cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma	NCT04225429	Epithelioid Sar...	Tazemetostat	18 Years -	Ipsen
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma	NCT04136808	Locally Advance...	enfortumab vedo...	18 Years -	Astellas Pharma Inc
Expanded Access to Navitoclax	NCT03592576	Myelofibrosis Acute Lymphocyt... Lymphoblastic L...	Navitoclax Venetoclax	4 Years -	AbbVie
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma	NCT04571229	Osteosarcoma	L-MTP-PE	-	Memorial Sloan Kettering Cancer Center
CTL019 Out of Specification MAP for ALL or DLBCL Patients	NCT03601442	Acute Lymphobla... Diffuse Large B...	CTL019	1 Day - 25 Years	Novartis
An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma	NCT04136808	Locally Advance...	enfortumab vedo...	18 Years -	Astellas Pharma Inc
Expanded Access to Omaveloxolone for Melanoma for Patients Previously Enrolled in 408-C-1401	NCT03593499	Melanoma	omaveloxolone	-	Biogen
Expanded Access to Veliparib	NCT03123211	Solid Tumors Wi... Triple Negative... High Grade Sero... Patients Requir...	Veliparib	-	AbbVie
Expanded Access to ABBV-400	NCT05982873	Non-Small Cell ...	ABBV-400	18 Years -	AbbVie
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome	NCT02189720	Congenital Myas... Lambert-Eaton M... Nystagmus, Acqu...	Amifampridine P...	2 Years -	Catalyst Pharmaceuticals, Inc.
Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer	NCT04473040	HR+, HER2-, Adv...	alpelisib	18 Years - 99 Years	Novartis
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma	NCT02204553	Multiple Myelom...	Panobinostat	18 Years -	Novartis
Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma	NCT04571229	Osteosarcoma	L-MTP-PE	-	Memorial Sloan Kettering Cancer Center
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	NCT03409081	Acute Myeloid L... FMS-like Tyrosi...	gilteritinib	18 Years -	Astellas Pharma Inc
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma	NCT04225429	Epithelioid Sar...	Tazemetostat	18 Years -	Ipsen
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome	NCT02189720	Congenital Myas... Lambert-Eaton M... Nystagmus, Acqu...	Amifampridine P...	2 Years -	Catalyst Pharmaceuticals, Inc.
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation	NCT05162443	Advanced Cancer Metastatic Canc... Malignant Neopl...	adagrasib (MRTX...	18 Years -	Mirati Therapeutics Inc.
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation	NCT05162443	Advanced Cancer Metastatic Canc... Malignant Neopl...	adagrasib (MRTX...	18 Years -	Mirati Therapeutics Inc.
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release	NCT04771078	Multiple Myelom...	Nonconforming i...	18 Years -	Celgene
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	NCT03070093	Acute Myeloid L... FMS-like Tyrosi...	gilteritinib	18 Years -	Astellas Pharma Inc
Expanded Access for Marizomib	NCT04644107	Solid Tumor	Marizomib	18 Years -	Celgene
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie
CTL019 Out of Specification MAP for ALL or DLBCL Patients	NCT03601442	Acute Lymphobla... Diffuse Large B...	CTL019	1 Day - 25 Years	Novartis
Expanded Access to Venetoclax	NCT03123029	Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... Non-Hodgkin's L... Acute Lymphobla... Amyloidosis Plasma Cell Leu...	Venetoclax	-	AbbVie
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	NCT03070093	Acute Myeloid L... FMS-like Tyrosi...	gilteritinib	18 Years -	Astellas Pharma Inc
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor	NCT04100694	NRG1 Fusion Pancreatic Canc... Non Small Cell ... Solid Tumor, Un... Prostate Cancer Head and Neck C... Colorectal Canc... Breast Cancer Cholangiocarcin... Renal Cell Carc... Unknown Primary...	MCLA-128	18 Years -	Merus N.V.
Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer	NCT04473040	HR+, HER2-, Adv...	alpelisib	18 Years - 99 Years	Novartis

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: